TABLE 5.
Use of individual sulfonylurea drugs and risk of out‐of‐hospital cardiac arrest compared to use of glimepiride
| Cases | Controls | Crude OR | Adjusted OR | Adjusted OR | |
|---|---|---|---|---|---|
| (n = 219) | (n = 697) | (model 1) | (model 2) | (model 3) | |
| Glimepiride | 58 (26.5) | 164 (23.5) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) |
| Glibenclamide | 12 (5.5) | 29 (4.2) | 1.2 (0.6–2.5) | 1.3 (0.6–2.7) | 1.3 (0.6–2.7) |
| Gliclazide | 16 (7.3) | 101 (14.5) | 0.5 (0.3–0.8) | 0.5 (0.3–0.9) | 0.5 (0.3–0.9) |
| Tolbutamide | 23 (10.5) | 125 (17.9) | 0.5 (0.3–0.9) | 0.6 (0.3–1.002) | 0.6 (0.3–1.002) |
Not included in the table: Three controls that used multiple sulfonylurea drugs concomitantly and no users of SU drugs. Use of individual sulfonylurea drugs was defined as use within 90 days before the index‐date.
Model 1: OR adjusted for age and sex.
Model 2: OR adjusted for age, sex, use of cardiovascular drugs, Vaughan‐Williams class 1 or 3 antiarrhythmic drugs and non‐cardiac QT‐prolonging drugs.
Model 3: OR adjusted for age, sex, use of cardiovascular drugs, Vaughan‐Williams class 1 or 3 antiarrhythmic drugs, non‐cardiac QT‐prolonging drugs and diabetes severity.